Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Reducing the severity of respiratory disease
The effect of immune-modulators in equine medicine

An Animal Health Trust (AHT) review has found that immune-modulators can reduce the severity of some respiratory diseases in horses.

The review, which has been published in Veterinary Immunology and Immunopathology, was conducted by Romain Paillot, who works at AHT.

His work involved examining scientific literature and reports on the use of immune-modulators in equine medicine, in particular, for the prevention or treatment of respiratory disease.

The two immune-modulators studied were Parapoxvirus ovis (iPPVO) and Propionbacterium acnes (P.acnes), which are both used to improve immune defences and prevent or treat infectious diseases in horses.

Dr Paillot found that young horses treated with iPPVO and co-mingled with experimentally infected EHV-1 horses showed a reduction in disease severity by 40 per cent.

Meanwhile, those treated with iPPVO and co-mingled with horses experimentally infected with EHV-4 showed a 61 per cent reduction in disease severity.

For horses treated with P.acnes, Dr Paillot found that the frequency of recovery for horses that had shown clinical signs of respiratory disease were "significantly increased".

He said: "Non-specific immune-modulators such as iPPVO or P.acnes may not provide protection against direct infection or transmission of respiratory pathogens, but they seem to contribute to the reduction of the disease severity.

"This subsequently reduces the frequency of complications and improves the rate of recovery."

Click here to read the review.

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
BVA urges 'continued vigilance' over bluetongue

The British Veterinary Association (BVA) has urged vigilance following a concerning rise in Bluetongue (BTV) cases in sheep and cattle.

In a recent statement, the BVA noted that members are reporting more severe clinical signs and higher mortality rates than in previous years.

'We know that farm vets are working hard to support farmers and animals affected by this outbreak, during what is an extremely difficult time for all involved,' they stated. 'Continued vigilance to identify disease early is vital and vaccination remains the best way of protecting animals from this disease.'